Valo Therapeutics Appoints Experienced Life Sciences Executive Anthony Giovinazzo to Board
Helsinki, Finland, 27 June 2022 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the appointment of an accomplished life sciences executive. Anthony Giovinazzo will bring his considerable track record of capital raising, drug development, and company leadership in North America to the company’s Board of Directors. In addition to his general Board role, Anthony will also join the GNC and Audit Committees.
